Abciximab Drug info with Brand name and Price

Abciximab

Abciximab Classifications

• Therapeutic Classification:antiplatelet agents
• Pharmacologic Classification:glycoprotein iib iiia inhibitors
• Platelet Glycoprotein  IIb/IIIa Receptor Antagonist
• SCHEDULE: H
• Category C
• STORAGE: Refrigerate at 2-8’C. Do not freeze.

DOSAGE:

• Intravenous
• STABILlSATION IN PATIENTS WLJH UNSTABLE ANGINA: Adult: 250 , mcglkg body weight bolus injection over 1 min followed by 0.125 mcglkg body weight/min infusion, started up to 24 hrs before and 12 hrs after the possible intervention. Max Dose: 10 mcg/min infusion.
• ADJUNCT FOR THE PREVENTION OF ACUTE ISCHAEMIC COMPLICATIONS IN PERCUTANEOUS TRANSLUMINAL CORONARY PROCEDURES: Adult: 250 mcglkg body weight bolus injection over 1 min followed by 0.125 mcg/kg body weight/min infusion. Max Dose: 10 mcglmin infusion.

Contraindicated of Abciximab in:

• Hypersensitivity to abciximab or murine (mouse) protein.
• Active internal bleeding.
• Recent significant GI or GU bleeding (within 6 wk).
• History of CVA (within 2 yr) or CVA with neurologic sequelae.
• History of bleeding disorder.
• Recent (within 7 days) oral anticoagulant therapy (PT 1.2 times control).
• Platelet count <100,000 cells/mm³.
• Recent trauma or major surgery (within 6 wk).
• Intracranial neoplasm.
• Aneurysm or AV malformation.
• Severe uncontrolled hypertension.
• History of vasculitis.
• Concurrent use of another parenteral GP IIb/IIIa inhibitor.
• Recent or concurrent dextran therapy.
• Cl: Hypersensitivity to any component or to murine proteins; active bleeding; patients at increased risk of haemorrhage, recent (within 6 weeks) GI or genitourinary bleeding of clinical
• significance; history of cerebrovascular accident (CV A) within 2 yrs or CVA with a significant residual neurological deficit; bleeding diathesis; thrombocytopaenia (10,000 cells/microlitre); clotting abnormalities; administration of oral anticoagulants within 7 days; recent (within 6 weeks) major surgery or trauma; intracranial turner, arteriovenous malformation or aneurysm; severe uncontrolled hypertension; severe renal or hepatic impairment presumed or documented history of vasculitis; use of IV dextran before PTCA, or intent of use during PCTA.
• SP: Elderly >65 yrs, recent thrombolytic therapy, unsuccessful PTCA. During readministration; use with thrombolytics, anticoagulants and other antiplatelet agents; while obtaining IV route and/or during arterial and venous punctureslintubations; measure platelet count, prothrombin time and APTT to identify preexisting haemostatic abnormalities, before administration; pregnancy and lactation: childn; patients weighing <75 kg.

Use Abciximab Cautiously in:

• Patients weighing <75 kg or >65 yr (increased risk of bleeding).
• History of previous GI pathology.
• Concurrent thrombolytic or heparin therapy.
• PCI within 12 hr of onset of MI symptoms or PCI procedure lasting >70 min.
• OB: Lactation: Pedi: Safety not established.

High Alert

• Used with heparin and aspirin to decrease cardiac ischemic complications before or after percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA).

Unlabeled Uses:

• In combination with heparin and and/or low-dose alteplase or reteplase to enhance coronary perfusion in patients with acute coronary syndromes (ACS).

Adv. Reactions/Side Effects of Abciximab

• CNS: abnormal thinking, dizziness , headache.
• CV: hypotension, atrial fibrillation/flutter , bradycardia, complete AV block, supraventricular tachycardia, vascular disorder, chest pain, peripheral edema.
• Hemat: bleeding, thrombocytopenia .

Availability

• Injection: 2 mg/ml in 5-ml vials

Abciximab Brand name and Price —

• REOPRO Eli Lilly VIAL 2mg/mL 10mg  Price Rs- 19740.00